Featured
Visual perception improves in the blink of an eye
The Transmitter Launch: Industry internships, ‘Next Generation Leaders,’ and more
Latest
What neuroscientists should know—and what they can do—about changes to BRAIN initiative funding
Carol Jennings, whose family’s genetics informed amyloid cascade hypothesis, dies at 70
Today’s action potentials
A previously unrecognized class of neurons emerges from a nanoscale reconstruction of 1 cubic millimeter of human brain tissue, according to a new study by Alexander Shapson-Coe, et al. in Science. The tissue sample, which extends from layer 1 to the white matter in the anterior middle temporal gyrus, contains about 57,000 cells and 150 million synapses, two-thirds of which are excitatory.
”I want to build a firewall here, between this [study] and support for rapid prompting. It does not, in my opinion, in any way, shape, or form support rapid prompting. — STEPHEN CAMARATA
Crowdsourcing to curb aggression in autism: Q&A with Matthew Goodwin
Where do cell states end and cell types begin?
To improve big data, we need small-scale human imaging studies
What, if anything, makes mood fundamentally different from memory?
Synaptic
The value of math and spatial learning with Loren Frank
Setting up a frog colony and pair bonding with Lauren O’Connell
Being uncomfortable and PKMzeta with André Fenton
Boost your writing with AI personas
From bench to bot: How to use AI to structure your writing
From bench to bot: How to use AI tools to convert notes into a draft
Larry Young built bridges with his social neuroscience research
Known for his work bringing oxytocin studies to the mainstream, Young died unexpectedly last month.
The legacy of William Catterall, ‘father of ion channels’
Maiken Nedergaard’s power of disruption
Unleashing the power of DIY innovation in behavioral neuroscience
Pooling data points to new potential treatment for spinal cord injury
How scuba diving helped me embrace open science
Making cancer nervous
Nerve cells in the brain and throughout the body can turbocharge tumor growth — a finding that not only expands conventional ideas about the nervous system but points to novel therapeutic targets for a range of malignancies.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.